MGMT hypermethylation and MDR system in glioblastoma cancer stem cells

Cancer Genomics and Proteomics

Volumn 9, Issue 4, 2012, Pages 171-178

  Caldera, Valentina ^a   Mellai, Marta ^a   Annovazzi, Laura ^a   Monzeglio, Oriana ^a   Piazzi, Angela ^a,b   Schiffer, Davide ^a  

^a UNIVERSITY OF PAVIA   (Italy)

^b UNIVERSITY OF EASTERN PIEDMONT   (Italy)

Author keywords

Glioblastoma stem cells; MDR; MGMT

Indexed keywords

ABC TRANSPORTER; CANCER GROWTH FACTOR; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; MULTIDRUG RESISTANCE PROTEIN 1; PROTEIN ABC TRANSPORTER C1; TRANSMEMBRANE CONDUCTANCE REGULATOR; UNCLASSIFIED DRUG;

ADHERENT CELL; ADULT; AGED; ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CANCER STEM CELL; CELL LINE; CLINICAL ARTICLE; CONTROLLED STUDY; DNA METHYLATION; ENDOTHELIUM CELL; EPIGENETICS; FEMALE; GENE EXPRESSION; GENETIC ANALYSIS; GLIA CELL; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MULTIDRUG RESISTANCE; NUCLEOTIDE SEQUENCE; PRIMARY TUMOR; PROTEIN EXPRESSION; SERUM; TUMOR CELL;

EID: 84864720900     PISSN: 11096535     EISSN: 17906245     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Reya T, Morrison SJ, Clarke MF and Weissman IL: Stem cells, cancer, and cancer stem cells. Nature 414: 105-111, 2001. (Pubitemid 33041634)
2. Ignatova TN, Kukekov VG, Laywell ED, Suslov ON, Vrionis FD and Steindler DA: Human cortical glial tumors contain neural stem-like cells expressing astroglial and neuronal markers in vitro. Glia 39: 193-206, 2002.
3. Galli R, Binda E, Orfanelli U, Cipelletti B, Gritti A, De Vitis S, Fiocco R, Foroni C, Dimeco F and Vescovi A: Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res 64: 7011-7021, 2004. (Pubitemid 39331011)
4. Yuan X, Curtin J, Xiong Y, Liu G, Waschsmann-Hogiu S, Farkas DL, Black KL and Yu JS: Isolation of cancer stem cells from adult glioblastoma multiforme. Oncogene 23: 9392-400, 2004. (Pubitemid 40069671)
5. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM, Cusimano MD and Dirks PB: Identification of human brain tumour-initiating cells. Nature 432: 396-401, 2004. (Pubitemid 39551674)
6. Lee J, Kotliarova S, Kotliarov Y, Li A, Su Q, Donin NM, Pastorino S, Purow BW, Christopher N, Zhang W, Park JK and Fine HA: Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines, Cancer Cell 9: 391-403, 2006. (Pubitemid 43668737)
7. Sanai N, Alvarez-Buylla A and Berger MS: Neural stem cells and the origin of gliomas. N Engl J Med 353: 811-822, 2005.
8. Liu Z, Hu X, Cai J, Liu B, Peng X, Wegner M and Qiu M: Induction of oligodendrocyte differentiation by Olig2 and Sox10: evidence for reciprocal interactions and dosage-dependent mechanisms. Dev Biol 302: 683-693, 2007. (Pubitemid 46216266)
9. Stiles CD and Rowitch DH: Glioma stem cells: a midterm exam. Neuron 58: 832-846, 2008. (Pubitemid 351842757)
10. Uchida K, Mukai M, Okano H and Kawase T: Possible oncogenicity of subventricular zone neural stem cells: case report. Neurosurgery 55: 977-978, 2004. (Pubitemid 39315047)
11. Schiffer D, Manazza A and Tamagno I: Nestin expression in neuroepithelial tumors. Neurosci Lett 400: 80-85, 2006.
12. Caldera V, Mellai M, Annovazzi L, Piazzi A, Lanotte M, Cassoni P and Schiffer D: Antigenic and genotypic similarity between primary glioblastomas and their derived neurospheres. J Oncol 314962, 2011.
13. Vescovi AL, Galli R and Reynolds BA: Brain tumour stem cells. Nat Rev Cancer 6: 425-436, 2006.
14. Weiss WA, Burns MJ, Hackett C, Aldape K, Hill JR, Kuriyama H, Kuriyama N, Milshteyn N, Roberts T, Wendland MF, DePinho R and Israel MA: Genetic determinants of malignancy in a mouse model for oligodendroglioma. Cancer Res 63: 1589-1595, 2003. (Pubitemid 36373648)
15. Persson AI, Petritsch C, Swartling FJ, Itsara M, Sim FJ, Auvergne R, Goldenberg DD, Vandenberg SR, Nguyen KN, Yakovenko S, Ayers-Ringler J, Nishiyama A, Stallcup WB, Berger MS, Bergers G, McKnight TR, Goldman SA and Weiss WA: Non-stem cell origin for oligodendroglioma. Cancer Cell 18: 669-682, 2010.
16. Sugiarto S, Persson AI, Munoz EG, Waldhuber M, Lamagna C, Andor N, Hanecker P, Ayers-Ringler J, Phillips J, Siu J, Lim DA, Vandenberg S, Stallcup W, Berger MS, Bergers G, Weiss WA and Petritsch C: Asymmetry-defective oligodendrocyte progenitors are glioma precursors. Cancer Cell 20: 328-340, 2011.
17. Conti L and Cattaneo E: Neural stem cell systems: physiological players or in vitro entities?. Nat Rev Neurosci 11: 176-187, 2010; erratum in: Nat Rev Neurosci 11: 782, 2010.
18. Natsume A, Kinjo S, Yuki K, Kato T, Ohno M, Motomura K, Iwami K and Wakabayashi T: Glioma-initiating cells and molecular pathology: Implications for therapy. Brain Tumor Pathol 28: 1-12, 2011.
19. Reynolds BA and Vescovi AL: Brain cancer stem cells: Think twice before going flat. Cell Stem Cell 5: 466-467, 2009.
20. Pollard M, Yoshikawa K, Clarke ID, Danovi D, Stricker S, Russell R, Bayani J, Head R, Lee M, Bernstein M, Squire JA, Smith A and Dirks P: Glioma stem cell lines expanded in adherent culture have tumor-specific phenotypes and are suitable for chemical and genetic screens. Cell Stem Cell 4: 568-580, 2009.
21. Günther HS, Schmidt NO, Phillips HS, Kemming D, Kharbanda S, Soriano R, Modrusan Z, Meissner H, Westphal M and Lamszus K: Glioblastoma-derived stem cell-enriched cultures form distinct subgroups according to molecular and phenotypic criteria. Oncogene 27: 2897-2909, 2008.
22. Sarkaria JN, Kitange GJ, James CD, Plummer R, Calvert H, Weller M and Wick W: Mechanisms of chemoresistance to alkylating agents in malignant glioma. Clin Cancer Res 14: 2900-2908, 2008.
23. Johannessen TC, Bjerkvig R and Tysnes BB: DNA repair and cancer stem-like cells - Potential partners in glioma drug resistance? Cancer Treat Rev 34: 558-567, 2008.
24. Schmalz PGR, Shen MJ and Park JK: Treatment resistance mechanisms of malignant glioma tumor stem cells. Cancer 3: 621-635, 2011.
25. Louis DN, Ohgaki H, Wiestler OD, and Cavenee WK: WHO Classification of Tumors of the Central Nervous System 4th ed, Lyon, IARC, 2007.
26. Mellai M, Caldera V, Annovazzi L, Chiò A, Lanotte M, Cassoni P, Finocchiaro G and Schiffer D: MGMT promoter hypermethylation in a series of 104 glioblastomas. Cancer Genomics Proteomics 6: 219-227, 2009.
27. Reynolds BA and Weiss S: Generation of neurons and astrocytes from isolated cells of the adult mammalian central nervous system. Science 5052: 1707-1710, 1992.
28. Esteller M, Hamilton SR, Burger PC, Baylin SB and Herman JG: Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res 59: 793-797, 1999. (Pubitemid 29086728)
29. Mellai M, Monzeglio O, Piazzi A, Caldera V, Annovazzi L, Cassoni P, Valente G, Cordera S, Mocellini C and Schiffer D: MGMT promoter hypermethylation and its associations with genetic alterations in a series of 350 brain tumors. J Neurooncol Jan 28, 2012.
30. Jha P, Suri V, Jain A, Sharma MC, Pathak P, Jha P, Srivastava A, Suri A, Gupta D, Chosdol K, Chattopadhyay P and Sarkar C: O6-Methylguanine DNA methyltransferase gene promoter methylation status in gliomas and its correlation with other molecular alterations: first Indian report with review of challenges for use in customized treatment. Neurosurgery 67: 1681-1691, 2010.
31. Suri V, Jha P, Sharma MC and Sarkar C: O6-Methylguanine DNA methyltransferase gene promoter methylation in high-grade gliomas: A review of current status. Neurol India 59: 229-235, 2011.
32. Kang SH, Park KJ, Kim CY, Yu MO, Park CK, Park SH and Chung YG: O6-Methylguanine DNA methyltransferase status determined by promoter methylation and immunohistochemistry in gliosarcoma and their clinical implications. J Neurooncol 101: 477-486, 2011.
33. Komine C, Watanabe T, Katayama Y, Yoshino A, Yokoyama T and Fukushima T: Promoter hypermethylation of the DNA repair gene O6-methylguanine-DNA methyltransferase is an independent predictor of shortened progression-free survival in patients with low-grade diffuse astrocytomas. Brain Pathol 13: 176-184, 2003. (Pubitemid 36460818)
34. Watanabe T, Nakamura M, Kros JM, Burkhard C, Yonekawa Y, Kleihues P and Ohgaki H: Phenotype versus genotype correlation in oligodendrogliomas and low-grade diffuse astrocytomas. Acta Neuropathol 103: 267-275, 2002. (Pubitemid 36075328)
35. Everhard S, Kaloshi G, Crinière E Benouaich-Amiel A, Lejeune J, Marie Y, Sanson M, Kujas M, Mokhtari K, Hoang-Xuan K, Delattre JY and Thillet J: MGMT methylation: a marker of response to temozolomide in low-grade gliomas. Ann Neurol 60: 740-743, 2006.
36. Watanabe T, Katayama Y, Yoshino A, Yachi K, Ohta T, Ogino A, Komine C and Fukushima T: Aberrant hypermethylation of p14 ARF and O6-methylguanine-DNA methyltransferase genes in astrocytoma progression. Brain Pathol 17: 5-10, 2007.
37. Möllemann M, Wolter M, Felsberg J, Collins VP, Reifenberger G: Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors. Int J Cancer 113: 379-385, 2005.
38. Hegi ME, Diserens AC, Godard S, Dietrich PY, Regli L, Ostermann S, Otten P, Van Melle G, de Tribolet N and Stupp R: Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res 10: 1871-1874, 2004. (Pubitemid 38375541)
39. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC and Stupp R: MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352: 997-1003, 2005. (Pubitemid 40349502)
40. Eoli M, Menghi F, Bruzzone MG, De Simone T, Valletta L, Pollo B, Bissola L, Silvani A, Bianchessi D, D'Incerti L, Filippini G, Broggi G, Boiardi A and Finocchiaro G: Methylation of O6-methylguanine-DNA methyltransferase and loss of heterozygosity on 19q and/or 17p are overlapping features of secondary glioblastomas with prolonged survival. Clin Cancer Res 13: 2606-2613, 2007. (Pubitemid 46788026)
41. Nakamura M, Watanabe T, Yonekawa Y, Kleihues P and Ohgaki H: Promoter methylation of the DNA repair gene MGMT in astrocytomas is frequently associated with G:C → A:T mutations of the TP53 tumor suppressor gene. Carcinogenesis 22: 1715-1719, 2001. (Pubitemid 32952152)
42. Ohgaki H and Kleihues P: Genetic pathways to primary and secondary glioblastoma. Am J Pathol 170: 1445-1453, 2007. (Pubitemid 47339290)
43. Sciuscio D, Diserens AC, van Dommelen K, Martinet D, Jones G, Janzer RC, Pollo C, Hamou MF, Kaina B, Stupp R, Levivier M and Hegi ME: Extent and patterns of MGMT promoter methylation in glioblastoma- and respective glioblastoma-derived spheres. Clin Cancer Res 17: 255-266, 2011.
44. Groenendijk FH, Taal W, Dubbink HJ, Haarloo CR, Kouwenhoven MC, van den Bent MJ, Kros JM and Dinjens WN: MGMT promoter hypermethylation is a frequent, early, and consistent event in astrocytoma progression, and not correlated with TP53 mutation. J Neurooncol 101: 405-417, 2011.
45. Schiffer D, Caldera V, Mellai M, Annovazzi L: Glioblastoma cancer stem cells: basis for a functional hypothesis. Stem Cell Discovery. In press.
46. Liu G, Yuan X, Zeng Z, Tunici P, Ng H, Abdulkadir IR, Lu L, Irvin D, Black KL and Yu JS: Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol Cancer 5: 67, 2006.
47. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, Dewhirst MW, Bigner DD and Rich JN: Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444: 756-760, 2006. (Pubitemid 44949604)
48. Beaulieu E, Demeule M, Ghitescu L and Béliveau R: P-glycoprotein is strongly expressed in the luminal membranes of the endothelium of blood vessels in the brain. Biochem J 326: 539-544, 1997.
49. Tóth K, Vaughan MM, Peress NS, Slocum HK and Rustum YM: MDR1 P-glycoprotein is expressed by endothelial cells of newly formed capillaries in human gliomas but is not expressed in the neovasculature of other primary tumors. Am J Pathol 149: 853-858, 1996.
50. Nakai E, Park K, Yawata T, Chihara T, Kumazawa A, Nakabayashi H and Shimizu K: Enhanced MDR1 expression and chemoresistance of cancer stem cells derived from glioblastoma. Cancer Invest 27: 901-908, 2009.
51. Spiegl-Kreinecker S, Buchroithner J, Elbling L, Steiner E, Wurm G, Bodenteich A, Fischer J, Micksche M and Berger W: Expression and functional activity of the ABC-transporter proteins P-glycoprotein and multidrug-resistance protein 1 in human brain tumor cells and astrocytes. J Neurooncol 57: 27-36, 2002. (Pubitemid 34692611)
52. Calatozzolo C, Gelati M, Ciusani E, Sciacca FL, Pollo B, Cajola L, Marras C, Silvani A, Vitellaro-Zuccarello L, Croci D, Boiardi A and Salmaggi A: Expression of drug resistance proteins Pgp, MRP1, MRP3, MRP5 and GST-π in human glioma. J Neurooncol 74: 113-121, 2005. (Pubitemid 41478906)
53. Salmaggi A, Boiardi A, Gelati M, Russo A, Calatozzolo C, Ciusani E, Sciacca FL, Ottolina A, Parati EA, La Porta C, Alessandri G, Marras C, Croci D and De Rossi M: Glioblastoma-derived tumorospheres identify a population of tumor stem-like cells with angiogenic potential and enhanced multidrug resistance phenotype. Glia 54: 850-860, 2006. (Pubitemid 44671990)
54. Declèves X, Fajac A, Lehmann-Che J, Tardy M, Mercier C, Hurbain I, Laplanche JL, Bernaudin JF and Scherrmann JM: Molecular and functional MDR1-Pgp and MRPs expression in human glioblastoma multiforme cell lines. Int J Cancer 98: 173-180, 2002.
55. Mohri M, Nitta H and Yamashita J: Expression of multidrug resistance-associated protein (MRP) in human gliomas. J Neurooncol 49: 105-115, 2000. (Pubitemid 32058517)